Irdabisant hydrochloride

Synonyms: CEP-26401 hydrochloride
Irdabisant (CEP-26401) hydrochloride 是一种选择性、口服活性且可穿透血脑屏障的组胺 H3 受体 (histamine H3 receptor, H3R) 拮抗剂/逆激动剂,对大鼠 H3R 和人 H3R 的 Ki 分别为 7.2 nM 和 2.0 nM,对 hERG 电流的抑制活性相对较低(IC50 为 13.8 μM),在大鼠社会认知模型中具有认知增强和唤醒作用,可用于精神分裂症或认知障碍的研究。
产品编号: MS-A13627 CAS No.: 1005398-61-7 分子式: C18H24ClN3O2 分子量: 349.86
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Irdabisant (CEP-26401) hydrochloride 是一种选择性、口服活性且可穿透血脑屏障的组胺 H3 受体 (histamine H3 receptor, H3R) 拮抗剂/逆激动剂,对大鼠 H3R 和人 H3R 的 Ki 分别为 7.2 nM 和 2.0 nM,对 hERG 电流的抑制活性相对较低(IC50 为 13.8 μM),在大鼠社会认知模型中具有认知增强和唤醒作用,可用于精神分裂症或认知障碍的研究。

生物实验数据

生物活性 Irdabisant (CEP-26401) hydrochloride is a selective, orally active, and blood-brain barrier-penetrant histamine H3 receptor (H3R) antagonist/inverse agonist with Ki values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively, exhibits relatively low inhibitory activity against hERG current with an IC50 of 13.8 μM, demonstrates cognitive-enhancing and wake-promoting effects in a rat social cognition model, and can be used for research on schizophrenia or cognitive disorders.
IC50 & Target H3 receptor (rat):7.2 nM (Ki), H3 receptor (human):2 nM (Ki)
体外研究
(In Vitro)

Irdabisant (CEP-26401, compound 8a) shows antagonist activity with Kb, app values of 1.0 nM and 0.4 nM for rat H3R and human H3R, respectively; shows inverse agonist activity with EC50 values of 2.0 nM and 1.1 nM for rat H3R and human H3R, respectively.
Irdabisant has moderate activity at Muscarinic M2 (Ki = 3.7 ± 0.0 μM) and Adrenergic α1A (Ki = 9.8 ± 0.3 μM) receptors, Dopamine transporters (Ki = 11 ± 2 μM), Norepinephrine transporters (Ki = 10 ± 1 μM), and phosphodiesterase PDE3 (IC50 = 15 ± 1 μM).
Irdabisant inhibits the cytochrome P450 enzymes CYP1A2, 2C9, 2C19, 2D6, and 3A4 with IC50 values of greater than 30 μM, indicating less potential for drug-drug interactions.

体内研究
(In Vivo)

CEP-26401 (0.01-0.3 mg/kg; p.o.; single dosage) dose-dependently inhibits H3R agonist RAMH-induced dipsogenia.
CEP-26401 (0.0001-0.1 mg/kg; i.v. or p.o.; single dosage) improves performance in the rat social recognition model of short-term memory.
CEP-26401 (3-30 mg/kg; p.o.; single dosage) exhibits wake-promoting activity in rat.
CEP-26401 (3-30 mg/kg; i.p.) increases prepulse inhibition (PPI) in DBA/2NCrl mice.
CEP-26401 (1 mg/kg for i.v. and 3 mg/kg for p.o.; single dosage) is rapidly absorbed with high oral bioavailability in rat and monkey, and shows a moderate clearance in monkey and dog compared to the rat.
Pharmacokinetic Parameters of Irdabisant (compound 8a) in rats, dogs and monkeys.

Rat Dog Monkey
i.v. t1/2 (h) 2.6 2.9 5.4
i.v. Vd (L/kg) 9.4 3.5 ± 1.1 3.8 ± 0.9
i.v. CL (mL/min/kg) 42 13.2 ± 1.5 7.7 ± 1.8
p.o. t1/2 (L/kg) 2.9 2.7 5.0
p.o. AUC (ng·h/mL) 984 1190 ± 180 1919 ± 611
p.o. Cmax (ng/mL) 270 230 ± 70 760 ± 74
p.o. F (%) 83 22 ± 2 83 ± 18
Brain to plasma ratio 2.6 ± 0.2 2.4 ± 0.4 /

Animal Model: Male Sprague-Dawley rats (i.p. 10 mg/kg RAMH-induced dipsogenia model)
Dosage: 0.01-0.3 mg/kg
Administration: p.o.; single dosage
Result: Dose-dependently inhibited H3R agonist RAMH (MS-V48092)-induced dipsogenia (which manifests as water drinking) with an EC50 value of 0.06 mg/kg.
Animal Model: Male Sprague-Dawley rats (adult rats were briefly exposed to a juvenile rat for build social recognition model)
Dosage: 0.0001, 0.001, 0.01 and 0.1 mg/kg for i.p.; 0.01 and 0.1 mg/kg for p.o.
Administration: i.v. or p.o.; single dosage
Result: Effectively reduced the ratio of investigation duration (RID) at doses over the range from 0.001 to 0.1 mg/kg i.p. and at 0.01 and 0.1 mg/kg p.o., demonstrating potent enhancement of short-term sensory memory in this model.
Animal Model: Male Sprague-Dawley rats
Dosage: 3, 10 and 30 mg/kg
Administration: p.o.; single dosage
Result: Exhibited robust wake promotion with the treated animals awake 90% of the time up to 3 h postdosing at 30 mg/kg.
Animal Model: Male Sprague-Dawley rats, male beagle dogs and male cynomolgus monkeys
Dosage: 1 mg/kg for i.v. and 3 mg/kg for p.o.
Administration: i.v. and p.o.
Result: Exhibited rapid absorption with high oral bioavailability in rat and monkey, and showed a moderate clearance in monkey and dog compared to the rat.
Animal Model: Male DBA/2NCrl mice (19-27 g; 7-9 weeks)
Dosage: 3, 10 and 30 mg/kg
Administration: i.p.; single dosage
Result: Increased prepulse inhibition (PPI) in DBA/2NCrl mice, whereas the antipsychotic Risperidone (MS-W78043) is effective at 0.3 and 1 mg/kg i.p..

化学信息

分子量 349.86
分子式 C18H24ClN3O2
CAS No. 1005398-61-7
别名 CEP-26401 hydrochloride

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础